deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.

Certain embodiments are described herein, including the best mode known to the inventors for carrying out the invention. Of course, variations on these described embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventor expects skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than specifically described herein. Accordingly, the claims include all modifications and equivalents of the subject matter recited in the claims as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is contemplated unless otherwise indicated herein or otherwise clearly contradicted by context.

In closing, it is to be understood that the embodiments disclosed herein are illustrative of the principles of the claims. Other modifications that may be employed are within the scope of the claims. Thus, by way of example, but not of limitation, alternative embodiments may be utilized in accordance with the teachings herein. Accordingly, the claims are not limited to embodiments precisely as shown and described.

What is claimed is:

1. A method of treating knee pain comprising orally administering a dosage form to a mammal in need thereof, wherein the dosage form comprises:

(Compound A)



A; and

(Compound B)



in an amount that is less than 0.1% w/w, and greater than 0% w/w; or

(Compound C)



in an amount that is less than 0.1% w/w, and greater than 0% w/w;

wherein any amount in % w/w is based upon the total weight of Compound A, Compound B, and Compound C;

wherein each A is independently an acidic functional group;

wherein, if present, the bioavailability of zoledronic acid in the dosage form is from about 1.1% to about 4%.

2. A method of treating knee pain comprising orally administering a dosage form to a human being suffering from knee pain, wherein the dosage form comprises:

a) zoledronic acid; or

b) one of the following:

1) zoledronic acid and

(Compound 1)



in an amount that is less than 0.1% w/w and greater than 0% w/w;

2) zoledronic acid and

(Compound 2)



in an amount that is less than 0.1% w/w and greater than 0% w/w;

or

3) zoledronic acid and a combination of Compound 1 in an amount that is less than 0.1% w/w and greater than 0% w/w, and Compound 2 in an amount that is less than 0.1% w/w and greater than 0% w/w;

wherein the dosage form is free of therapeutically active agents that are not zoledronic acid, Compound 1, or Compound 2;

wherein any amount in % w/w is based upon the total weight of zoledronic acid, Compound 1, and Compound 2; and

wherein the bioavailability of zoledronic acid in the dosage form is from about 1.1% to about 4%.

3. The method of claim **2**, wherein the dosage form is administered in an amount and frequency that results in an AUC of zoledronic acid, over a four week period, that is about 100 ng·h/mL to about 2000 ng·h/mL.

4. The method of claim **2**, wherein the dosage form is administered in an amount that results in an AUC of zoledronic acid, over a twenty-four hour period, that is about 20 ng·h/mL to about 500 ng·h/mL.

5. The method of claim **2**, wherein the dosage form is administered in an amount such that a monthly dose of zoledronic acid is about 1 mg to about 600 mg.

6. The method of claim **2**, wherein the dosage form is administered in an amount such that a monthly dose of zoledronic acid is about 10 mg to about 600 mg.

7. The method of claim **2**, wherein the dosage form is administered in an amount such that a monthly dose of zoledronic acid is about 20 mg to about 500 mg.

8. The method of claim **2**, wherein the dosage form is administered in an amount such that a monthly dose of zoledronic acid is about 50 mg to about 300 mg.

9. The method of claim **2**, wherein the dosage form is administered in an amount such that a monthly dose of zoledronic acid is about 200 mg to about 300 mg.

10. The method of claim **2**, wherein the dosage form is administered once a day.

11. The method of claim **2**, wherein the dosage form is administered 1 to 5 times a month.